At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
PF-3512676 +1 moredrug
Likely dose
PF-3512676 18 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Intratumoral Injection PF-3512676 in Combination With Local Radiation in Low-Grade B-Cell Lymphomas
In Brief
A Phase 2 clinical trial evaluating PF-3512676 and Local radiotherapy for Lymphoma, Non-Hodgkin and 3 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
To assess the feasibility of using intra-tumoral PF-3512676 in combination with local radiation as a therapy for lowgrade b-cell lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Non-Hodgkin, Lymphoma, Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell, Lymphomas: Non-Hodgkin
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedApr 2009
Primary CompletionSep 2011
Study CompletionJan 2015
TodayJul 2026
First PostedApr 14, 2009
Enrollment StartJan 1, 2009
Primary CompletionSep 1, 2011
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 17.2 years ago
Interventions
PF-3512676drug
18 mg injection
Local radiotherapyradiation
2 gray (2 Gy) on each of Days 1 and 2